BRPI0923183A8 - derivados de arilciclopropilacetamida úteis como ativadores da glicoquinase. - Google Patents

derivados de arilciclopropilacetamida úteis como ativadores da glicoquinase.

Info

Publication number
BRPI0923183A8
BRPI0923183A8 BRPI0923183A BRPI0923183A BRPI0923183A8 BR PI0923183 A8 BRPI0923183 A8 BR PI0923183A8 BR PI0923183 A BRPI0923183 A BR PI0923183A BR PI0923183 A BRPI0923183 A BR PI0923183A BR PI0923183 A8 BRPI0923183 A8 BR PI0923183A8
Authority
BR
Brazil
Prior art keywords
derivatives useful
arylcyclopropylacetamide
glycokinase activators
glycokinase
activators
Prior art date
Application number
BRPI0923183A
Other languages
English (en)
Inventor
Belen Bueno Melendo Ana
Javier Agejas-Chicharro Francisco
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BRPI0923183A2 publication Critical patent/BRPI0923183A2/pt
Publication of BRPI0923183A8 publication Critical patent/BRPI0923183A8/pt
Publication of BRPI0923183B1 publication Critical patent/BRPI0923183B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0923183-8A 2008-12-19 2009-12-11 Derivados de arilciclopropilacetamida úteis como ativadores da glicoquinase, e composição farmacêutica BRPI0923183B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP08380341.1 2008-12-19
EP08380341 2008-12-19
US15378109P 2009-02-19 2009-02-19
US61/153,781 2009-02-19
PCT/US2009/067603 WO2010080333A1 (en) 2008-12-19 2009-12-11 Arylcyclopropylacetamide derivatives useful as glucokinase activators

Publications (3)

Publication Number Publication Date
BRPI0923183A2 BRPI0923183A2 (pt) 2016-02-16
BRPI0923183A8 true BRPI0923183A8 (pt) 2017-09-12
BRPI0923183B1 BRPI0923183B1 (pt) 2019-03-19

Family

ID=40545955

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0923183-8A BRPI0923183B1 (pt) 2008-12-19 2009-12-11 Derivados de arilciclopropilacetamida úteis como ativadores da glicoquinase, e composição farmacêutica

Country Status (34)

Country Link
US (1) US8063079B2 (pt)
EP (1) EP2379517B1 (pt)
JP (1) JP5497064B2 (pt)
KR (1) KR101290437B1 (pt)
CN (1) CN102256952B (pt)
AR (1) AR074470A1 (pt)
AU (1) AU2009335931B2 (pt)
BR (1) BRPI0923183B1 (pt)
CA (1) CA2746746C (pt)
CO (1) CO6382120A2 (pt)
CR (1) CR20110342A (pt)
DK (1) DK2379517T3 (pt)
DO (1) DOP2011000197A (pt)
EA (1) EA019055B1 (pt)
EC (1) ECSP11011150A (pt)
ES (1) ES2435242T3 (pt)
HR (1) HRP20130983T1 (pt)
IL (1) IL213210A (pt)
JO (1) JO2979B1 (pt)
MA (1) MA32902B1 (pt)
MX (1) MX2011006434A (pt)
MY (1) MY180567A (pt)
NZ (1) NZ592930A (pt)
PA (1) PA8851901A1 (pt)
PE (1) PE20120339A1 (pt)
PL (1) PL2379517T3 (pt)
PT (1) PT2379517E (pt)
SG (1) SG172256A1 (pt)
SI (1) SI2379517T1 (pt)
TN (1) TN2011000294A1 (pt)
TW (1) TWI395748B (pt)
UA (1) UA104742C2 (pt)
WO (1) WO2010080333A1 (pt)
ZA (1) ZA201103944B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2553086B1 (en) 2010-03-31 2017-04-19 The Scripps Research Institute Reprogramming cells
CN110302394A (zh) 2013-11-22 2019-10-08 国立大学法人东京大学 药物递送用载体、偶联物及含有这些成分的组合物以及它们的施予方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2407416C (en) 2000-05-03 2006-07-18 Paige Erin Mahaney Alkynyl phenyl heteroaromatic glucokinase activators
DK1283830T3 (da) 2000-05-08 2008-08-25 Hoffmann La Roche Para-amin-substituerede phenylamidglucokinase-aktivatorer
EP1282611B1 (en) 2000-05-08 2004-10-20 F. Hoffmann-La Roche Ag Substituted phenylacetamides and their use as glucokinase activators
MY141521A (en) * 2002-12-12 2010-05-14 Hoffmann La Roche 5-substituted-six-membered heteroaromatic glucokinase activators
WO2004063179A1 (en) * 2003-01-06 2004-07-29 Eli Lilly And Company Substituted arylcyclopropylacetamides as glucokinase activators
PL378117A1 (pl) 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
EP1594863A1 (en) 2003-02-11 2005-11-16 Prosidion Limited Tri(cyclo) substituted amide glucokinase activator compounds
MXPA05009059A (es) * 2003-02-26 2005-10-19 Banyu Pharma Co Ltd Derivados de heteroarilcarbamoilbenceno.
EA012204B1 (ru) 2004-04-21 2009-08-28 Прозидион Лимитед Три(цикло)замещённые амидные соединения
AU2005271016A1 (en) 2004-08-12 2006-02-16 Prosidion Limited Substituted phenylacetamides and their use as glucokinase activators
US8148412B2 (en) * 2004-12-03 2012-04-03 Novo Nordisk A/S Heteroaromatic glucokinase activators
AU2006265653A1 (en) * 2005-07-01 2007-01-11 Novartis Ag Combination of a renin inhibitor and an insulin secretion enhancer or an insulin sensitizer
AR057661A1 (es) 2005-07-11 2007-12-12 Tanabe Seiyaku Co Un derivado de oxima y sus preparaciones
US20100160286A1 (en) * 2005-08-09 2010-06-24 Astrazeneca Uk Limited Ab Heteroarylcarbamoylbenzene derivatives for the treatment of diabetes
JP2009514835A (ja) 2005-11-03 2009-04-09 プロシディオン・リミテッド トリシクロ置換型アミド
US20080293741A1 (en) 2005-11-03 2008-11-27 Matthew Colin Thor Fyfe Tricyclo Substituted Amides as Glucokinase Modulators
EP1948645A1 (en) 2005-11-03 2008-07-30 Prosidion Limited Tricyclo substituted amides
MX2009000688A (es) * 2006-07-24 2009-01-30 Hoffmann La Roche Pirazoles como activadores de glucocinasa.
US8314247B2 (en) * 2007-01-10 2012-11-20 Mitsubishi Tanabe Pharma Corporation Hydrazone derivative
HRP20150842T1 (hr) 2008-04-28 2015-09-11 Kyorin Pharmaceutical Co., Ltd. Derivati ciklopentilakrilamida

Also Published As

Publication number Publication date
SI2379517T1 (sl) 2013-10-30
AR074470A1 (es) 2011-01-19
JO2979B1 (en) 2016-03-15
ZA201103944B (en) 2012-11-28
JP2012512874A (ja) 2012-06-07
PA8851901A1 (es) 2010-07-27
BRPI0923183B1 (pt) 2019-03-19
TWI395748B (zh) 2013-05-11
IL213210A0 (en) 2011-07-31
US8063079B2 (en) 2011-11-22
TW201029999A (en) 2010-08-16
KR101290437B1 (ko) 2013-07-29
NZ592930A (en) 2013-01-25
CN102256952B (zh) 2013-12-11
PE20120339A1 (es) 2012-04-16
JP5497064B2 (ja) 2014-05-21
MA32902B1 (fr) 2011-12-01
SG172256A1 (en) 2011-07-28
ECSP11011150A (es) 2011-07-29
EP2379517B1 (en) 2013-08-28
BRPI0923183A2 (pt) 2016-02-16
EP2379517A1 (en) 2011-10-26
MY180567A (en) 2020-12-02
DK2379517T3 (da) 2013-09-30
CO6382120A2 (es) 2012-02-15
US20100160395A1 (en) 2010-06-24
DOP2011000197A (es) 2011-09-15
CA2746746C (en) 2013-09-24
TN2011000294A1 (en) 2012-12-17
PT2379517E (pt) 2013-11-21
HRP20130983T1 (hr) 2013-11-22
CN102256952A (zh) 2011-11-23
KR20110086751A (ko) 2011-07-29
CR20110342A (es) 2011-09-14
EA019055B1 (ru) 2013-12-30
WO2010080333A1 (en) 2010-07-15
MX2011006434A (es) 2011-07-19
PL2379517T3 (pl) 2014-01-31
UA104742C2 (uk) 2014-03-11
AU2009335931A1 (en) 2011-07-07
ES2435242T3 (es) 2013-12-17
EA201170845A1 (ru) 2011-12-30
IL213210A (en) 2015-03-31
AU2009335931B2 (en) 2012-05-31
CA2746746A1 (en) 2010-07-15

Similar Documents

Publication Publication Date Title
BRPI0907925A2 (pt) Ativadores de glicoquinase.
BRPI0818658A2 (pt) Derivados de piridina úteis como ativadores de glicoquinase
BRPI0912802A2 (pt) ativadores de glicoquinase
BRPI0906625A2 (pt) Derivados de tio-2-amino-quinolina-6-substituída úteis como inibidores da beta-secretase (bace)
NO2021006I1 (no) Quofenix, delafloksacin
BRPI0919295A2 (pt) 1h-benzimidazol-5-carboxamidas como agentes anti-inflamatórios.
BRPI0915064A2 (pt) derivados de qunoxalinadiona
DK2308877T3 (da) Imidazopyridin-2-on-derivater
EP2344471A4 (en) 7-PIPERIDINALKYL-3,4-dihydroquinolone DERIVATIVE
BRPI0812825A2 (pt) Derivados ftalazinona como inibidores de parp-1
BRPI1008939A2 (pt) 2-mercaptoquinolina-3-carboxamidas substituídas como moduladores de kncq2/3.
EP2376493A4 (en) DIHYDROPYRIMIDOPYRIMIDINDERIVAT
BRPI0913832A2 (pt) derivados de pirrolopiridinilpirimidin-2-ilamina
EP2380877A4 (en) PYRIDINE-3-CARBONSÄUREAMIDDERIVAT
ATE555107T1 (de) 2-aza-bicyclo-ä2,2,1-üheptan-derivate
PT2860179T (pt) Derivados de pirazolo-piridina como inibidores de nadph-oxidase
BRPI0922391A2 (pt) pneumático.
BRPI0817562A2 (pt) derivados de n-hidroxilsulfonamida como novos doadores de niltroxil fisiologicamente úteis
BRPI0811044A2 (pt) 2-morfolin-4-il-pirimidinas como inibidores de p13k.
EP2336132A4 (en) MORPHOLINPURINDERIVAT
BRPI1014077A2 (pt) Derivados de tiazolilperidina como fungicidas
BRPI0917446A2 (pt) derivados de acilaminobenzamida.
DK2275414T3 (da) Cyclopentylacrylamidderivat
BRPI0909782A2 (pt) Derivados de azetidina
ATE527260T1 (de) (dihydro)pyrroloä2,1-aüisoquinoline

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/12/2009, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 12A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2648 DE 05-10-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.